Valuation: GENinCode Plc

Market Cap 5.46M 7.3M 6.52M 6.02M 10.21M 693M 10.38M 72.5M 28.7M 363M 27.41M 26.82M 1.15B P/E 2026 *
-1.02x
P/E 2027 * -
Enterprise Value 5.16M 6.9M 6.16M 5.69M 9.65M 655M 9.81M 68.51M 27.12M 343M 25.9M 25.35M 1.08B EV / Sales 2026 *
1.61x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day+16.00%
1 week+16.00%
Current month+3.57%
1 month-17.14%
3 months-9.38%
6 months-39.58%
Current year-69.79%
1 week 0.56
Extreme 0.561
0.85
1 month 0.56
Extreme 0.561
0.9
Current year 0.56
Extreme 0.561
2.5
1 year 0.56
Extreme 0.561
4.9
3 years 0.56
Extreme 0.561
10
5 years 0.56
Extreme 0.561
40
10 years 0.56
Extreme 0.561
48
Manager TitleAgeSince
Chief Operating Officer 51 05/09/2018
Chief Executive Officer 62 05/09/2018
Director of Finance/CFO 57 31/10/2020
Director TitleAgeSince
Chairman 62 05/09/2018
Director/Board Member 51 05/09/2018
Director/Board Member 65 30/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
06/05/26 Free

Founder

30,428,453 4.0407%
06/05/26 Free

Chairman

1,267,852 0.1684%
06/05/26 Free

Chief Financial Officer

13,523,757 1.7959%
Change 5-day change 1-year change 3-year change Capi.($)
+16.00%+16.00%-79.86%-91.21% 6.29M
+1.16%-1.13%-17.92%+8.27% 177B
-1.22%+0.70%+1.27%+31.80% 118B
+0.02%+4.24%-19.82%+16.53% 118B
+2.29%+21.86%-41.81%+11.12% 91.21B
-2.21%-2.91%+0.74%+75.30% 64.59B
-1.06%+4.59%+13.36%+78.58% 56.13B
-0.75%+3.73%+6.64%-22.28% 54.59B
-1.13%+0.00%-12.25%+31.02% 43.6B
+0.17%+5.12%-4.89%-10.48% 33.95B
Average +1.37%+3.80%-15.45%+12.87% 75.75B
Weighted average by Cap. +0.07%+3.55%-11.51%+22.76%

Financials

2026 *2027 *
Net sales 3.2M 4.28M 3.82M 3.53M 5.98M 406M 6.08M 42.45M 16.81M 213M 16.05M 15.71M 671M -
Net income -5.06M -6.77M -6.05M -5.58M -9.47M -643M -9.63M -67.2M -26.61M -337M -25.41M -24.87M -1.06B -
Net Debt -300K -401K -358K -331K -561K -38.09M -571K -3.98M -1.58M -19.96M -1.51M -1.47M -62.92M -
Projected Income Statement - Annual - GENinCode Plc
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
23/10/26 GBX 0.7250 +16.00% 7,773,428
22/10/26 GBX 0.6250 -3.85% 564,505
21/10/26 GBX 0.6500 -3.70% 4,233,806
20/10/26 GBX 0.6750 +12.50% 3,865,642
19/10/26 GBX 0.6000 -4.00% 1,374,835
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.006250GBP
Average target price
0.0750GBP
Spread / Average Target
+1,100.00%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - GENinCode Plc
  1. Stock Market
  2. Stocks
  3. GENI Stock